BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 21367748)

  • 1. Aberrations of EZH2 in cancer.
    Chase A; Cross NC
    Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
    Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V
    Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
    Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model for transmission of the H3K27me3 epigenetic mark.
    Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
    Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
    Simon JA; Lange CA
    Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 methyltransferase and H3K27 methylation in breast cancer.
    Yoo KH; Hennighausen L
    Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
    Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
    Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
    Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
    Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.